Acumen Pharmaceuticals, Inc. (ABOS) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Acumen Pharmaceuticals, Inc. (ABOS) Earnings Overview
As of June 28, 2026, Acumen Pharmaceuticals, Inc. (ABOS) reported trailing twelve-month net income of -$113M, reflecting -17.0% year-over-year growth. The company earned $-1.79 per diluted share over the past four quarters.
Looking at the long-term picture, ABOS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2020.
Acumen Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ATNM (-$23M net income, -37652.2% margin), SAVA (-$106M net income), ABOS has comparable earnings metrics. Compare ABOS vs PRAX →
ABOS Earnings vs Peers
Earnings metrics vs comparable public companies
ABOS Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$121M | -18.6% | -$124M | $-2.00 | - | - |
| 2024 | -$102M | -95.4% | -$114M | $-1.71 | - | - |
| 2023 | -$52M | -22.2% | -$61M | $-1.08 | - | - |
| 2022 | -$43M | +57.4% | -$45M | $-1.06 | - | - |
| 2021 | -$101M | -1273.5% | -$20M | $-2.63 | - | - |
| 2020 | -$7M | +7.4% | -$8M | $-0.26 | -510.1% | -551.0% |
| 2019 | -$8M | - | -$8M | $-0.27 | -465.9% | -459.9% |
Download Data
Export ABOS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABOS — Frequently Asked Questions
Quick answers to the most common questions about buying ABOS stock.
What is ABOS earnings per share (EPS)?
ABOS trailing twelve-month (TTM) diluted EPS is $-1.79, reflecting -17.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Acumen Pharmaceuticals, Inc.'s net income?
Acumen Pharmaceuticals, Inc. (ABOS) trailing twelve-month net income is $-113M as of 2025. Earnings declined -17.0% year-over-year.
Is ABOS profitable?
ABOS is not currently profitable on a TTM basis, reporting a net loss of $-113M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ABOS's earnings growth rate?
ABOS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are ABOS's profit margins?
Acumen Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -96.2%.
Is ABOS growing earnings?
ABOS earnings are declining — EPS fell -17.0% year-over-year. TTM net income dropped to $-113M. This contrasts with the 5-year CAGR of N/A.
What was ABOS's best earnings year?
Acumen Pharmaceuticals, Inc.'s highest annual net income on record is $-7M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were ABOS's earnings last quarter?
ABOS's most recent reported quarter was Q1 2026. Net income was $-21M with diluted EPS of $-0.33. For a full breakdown of all quarters, see the quarterly earnings table on this page.